Table 4.
ARIA findings by APOE ɛ4 carrier status and up-titration scheme in the OLEa
| Up-titration 1 | Up-titration 2 | Up-titration 3 | Up-titration 4 | Total | |
| Median (range) ARIA-E radiologic severity (assessed by BGTS)b | 5.00 (1.0–40.0) | 10.00 (1.0–25.0) | 15.50 (1.0–32.0) | 9.50 (4.0–20.0) | 9.00 (1.0–40.0) |
| New ARIA-E event, n/N (%) | |||||
| Carriersc | 22/58 (37.9) | – | 29/80 (36.3) | – | 51/138 (37.0) |
| 1ɛ4 | 11/38 (28.9) | – | 17/62 (27.4) | – | 28/100 (28.0) |
| 2ɛ4 | 11/20 (55.0) | – | 12/18 (66.7) | – | 23/38 (60.5) |
| Noncarriers | – | 9/33 (27.2) | 0/3 (0) | 10/45 (22.2) | 19/81 (23.5) |
| Recurrent ARIA-E event, n/N (%) | |||||
| Carriersc | 5/58 (8.6) | – | 8/80 (10.0) | – | 13/138 (9.4) |
| 1ɛ4 | 3/38 (7.9) | – | 5/62 (8.1) | – | 8/100 (8.0) |
| 2ɛ4 | 2/20 (10.0) | – | 3/18 (16.7) | – | 5/38 (13.2) |
| Noncarriers | – | 1/33 (3.0) | 0/3 (0) | 1/45 (2.2) | 2/81 (2.5) |
| New ARIA-H event, n/N (%) | |||||
| Carriersc | 23/58 (39.6) | – | 37/80 (46.3) | – | 60/138 (43.5) |
| 1ɛ4 | 13/38 (34.2) | – | 27/62 (43.5) | – | 40/100 (40.0) |
| 2ɛ4 | 10/20 (50.0) | – | 10/18 (55.6) | – | 20/38 (52.6) |
| Noncarriers | – | 8/33 (24.2) | 1/3 (33.3) | 6/45 (13.3) | 15/81 (18.5) |
| New ARIA-E and ARIA-H event, n/N (%) | |||||
| Carriersc | 17/58 (29.3) | – | 24/80 (30.0) | – | 41/138 (29.7) |
| 1ɛ4 | 9/38 (23.7) | – | 15/62 (24.2) | – | 24/100 (24.0) |
| 2ɛ4 | 8/20 (40.0) | – | 9/18 (50.0) | – | 17/38 (44.7) |
| Noncarriers | – | 4/33 (12.1) | 0/3 (0) | 3/45 (6.7) | 7/81 (8.6) |
aRefer to Fig. 2 for titration schemes. bBGTS radiologic severity scale correlates to three-point severity scale used in other studies.27 cIncludes those with either one (1ɛ4) or two (2ɛ4) copies of the APOE ɛ4. APOE ɛ4, apolipoprotein E ɛ4 allele; ARIA, amyloid-related imaging abnormalities; ARIA-E, amyloid-related imaging abnormalities – edema; ARIA-H, amyloid-related imaging abnormalities – hemorrhage; BGTS, Barkhof Grand Total Scale; OLE, open-label extension.